Investigation of genetic adaptation and venetoclax resistance in acute myeloid leukemia cells relapsed in a patient derived-xenograft model (Genetic adaptation and drug resistance in AML)

Kód projektu
MUNI/IGA/1371/2021
Období řešení
1/2022 - 12/2022
Investor / Programový rámec / typ projektu
Masarykova univerzita
Fakulta / Pracoviště MU
Lékařská fakulta

Acute myeloid leukemia (AML) is a hematologic malignancy with a 5-year survival of around 25%. Patient-derived xenografts (PDX) currently enable the most precise simulation of this disease.
This project aims to analyze mutation changes for two primary AMLs after in vivo treatment with experimental drugs – palbociclib and ponatinib, newly approved drugs in AML – venetoclax and azacitidine, and chemotherapy. For venetoclax, drug resistance and a possible drug synergism will also be analyzed.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info